RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-09 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
== External links == Genomics Directory Archived 2019-02-21 at the Wayback Machine: A one-stop biotechnology resource center for bioentrepreneurs, scientists, and students Pharmacometabolomics Research Network (PMRN) Human Metabolome Project Archived 2010-03-02 at the Wayback Machine:Project supported by Genome Alberta and Genome Canada Metabolomics Society: An organization dedicated to promoting the growth, use and understanding of metabolomics in the life sciences. Biological Magnetic Resonance Data Bank:A Repository for Data from NMR Spectroscopy on Proteins, Peptides, Nucleic Acids, and other Biomolecules Scripps Center for Metabolomics and Mass Spectrometry
(for the number of infected persons). The KdV-SIR equation shares the same form as the Korteweg–De Vries equation in the traveling wave coordinate. An analytical solution to the KdV-SIR equation is written as follows:
18 June: The New Zealand Government announces the scrapping of the five-yearly national census. The Māori iwi (tribe) Te Patutokotoko files legal action against Conservation Minister Tama Potaka and the Department of Conservation for not consulting them about granting ten-year concessions to Whakapapa Holdings Limited and Pure Tūroa to run the Tūroa and Whakapapa skifields. New World's Victoria Park supermarket in Auckland is extensively damaged during a major fire. 19 June – The New Zealand Government confirms it suspended NZ$20 million of core sector support funding to the Cook Islands in early June 2025 in retaliation for the Cook Islands government signing a partnership agreement with China without consulting New Zealand, per the requirements of their free association relationship. 20 June Prime Minister Christopher Luxon meets with Chinese President Xi Jinping in Beijing to discuss strengthening bilateral tourism, education and agricultural trade. The New Zealand Symphony Orchestra announces simultaneously the scheduled conclusion of the tenure of Gemma New as its artistic director and principal conductor in 2027, and the appointment of André de Ridder as its new music director, effective in 2027. 21 June – Brian Tamaki's Destiny Church stages a march in Auckland's Aotea Square opposing the spread of non-Christian religions and immigration in New Zealand. Destiny Church's actions are denounced by Minister for Ethnic Communities Mark Mitchell.
==== SEC/IEC ==== Hydrophobic interactions in protein SEC are relatively weak at low ionic strength, electrostatic effects may contribute significantly to retention, and this allows us to use an SEC column as a weak ion exchanger.
Sources: en.wikipedia.org
The September 11 terrorist attacks were a major turning point in Bush's presidency. That evening, he addressed the nation from the Oval Office, promising a strong response to the attacks. He also emphasized the need for the nation to come together and comfort the families of the victims. Three days after the attacks, Bush visited Ground Zero and met with then-New York City Mayor Rudy Giuliani, firefighters, police officers, and volunteers. Bush addressed the gathering via a megaphone while standing on rubble: "I can hear you. The rest of the world hears you. And the people who knocked these buildings down will hear all of us soon." In a September 20 speech, Bush condemned Osama bin Laden and his organization al-Qaeda, and issued an ultimatum to the Taliban regime in Afghanistan, where bin Laden was operating, to "hand over the terrorists, or ... share in their fate". The Taliban's leader, Mullah Omar, refused to hand over bin Laden. The continued presence of U.S. troops in Saudi Arabia after the 1991 Gulf War was one of the stated motivations behind the September 11 attacks. In 2003, the U.S. withdrew most of its troops from Saudi Arabia.
=== Helix structure === In 1948, Pauling discovered that many proteins included helical (see alpha helix) shapes. Pauling had deduced this structure from X-ray patterns and from attempts to physically model the structures. (Pauling was also later to suggest an incorrect three chain helical DNA structure based on Astbury's data.) Even in the initial diffraction data from DNA by Maurice Wilkins, it was evident that the structure involved helices. But this insight was only a beginning. There remained the questions of how many strands came together, whether this number was the same for every helix, whether the bases pointed toward the helical axis or away, and ultimately what were the explicit angles and coordinates of all the bonds and atoms. Such questions motivated the modeling efforts of Watson and Crick.
== Physical properties == The melting point of cerebrosides is considerably greater than physiological body temperature, >37.0 °C, giving glycolipids a paracrystalline, similar to liquid crystal structure. Cerebroside molecules are able form up to eight intermolecular hydrogen bonds between the polar hydrogens of the sugar and the hydroxy and amide groups of the sphingosine base of the ceramide. These hydrogen bonds within the cerebrosides result in the molecules having a high transition temperature and compact alignment. Monoglycosylceramides in conjunction with cholesterol are prevalent in the lipid-raft micro domain, which are important sites in the binding of proteins, and enzyme-receptor interactions.
=== El Mencho successor named === On 18 March 2026, the Wall Street Journal reported that a US Citizen named Juan Carlos Valencia González ("El Pelón"), who also uses the aliases "El Pelon," "El Tricky Tres," "03," "El 3," and "Pelacas," was now the CJNG's new leader. On 6 April 2026, El Pais would confirm that Valencia Gonzalez, El Mencho's stepson through his marriage to Rosalinda González Valencia, had successfully worked his way through the power vacuum created by El Mencho's death to succeed him as head of the CJNG as well. However, at the time of his capture in April 2026, it was acknowledged that CJNG second-in-command Audias Flores Silva ("El Jardinero") was making an effort to lead the organization as well.
=== Patents === Ayyappanpillai Ajayaghosh; Chakkooth Vijayakumar; Vakayil K. Praveen (10 September 2013). "White light emitting organogel and process thereof". Patent No. 8529790. {{cite journal}}: Cite journal requires |journal= (help) Ayyappanpillai Ajayaghosh; Sivaramapanicker Sreejith (1 January 2013). "Pyrrole end-capped bipyridine assay powder for selective detection of zinc ions and a process for the preparation thereof". Patent No. 8344150. {{cite journal}}: Cite journal requires |journal= (help) Ayyappanpillai Ajayaghosh; Sampath Srinivasan; Vakayil Praveen (4 December 2012). "Nanocomposite material useful for the preparation superhydrophobic coating and a process for the preparation thereof". Patent No. 8323732. {{cite journal}}: Cite journal requires |journal= (help)
Sources: en.wikipedia.org
Beta blockers act as β-adrenergic receptor antagonists. They may be non-selective, antagonizing both the β1- and β2-adrenergic receptors, or they may be selective for antagonism of the β1-adrenergic receptor (often referred to as "cardioselective"). Some beta blockers have intrinsic sympathomimetic activity (ISA), otherwise known as partial agonist activity at the β-adrenergic receptors with weak sympathomimetic effects. Some beta blockers are not selective for the β-adrenergic receptor and have additional α1-adrenergic receptor antagonism. Some beta blockers have membrane-stabilizing activity, otherwise known as sodium channel blockade or local anesthetic activity. Beta blockers vary in their lipophilicity versus hydrophilicity and hence in their capacity to cross the blood–brain barrier, with some having central nervous system effects and others being peripherally selective.
Urine Tears Perspiration Saliva Respiration Milk Faeces Bile Drugs are excreted from the kidney by glomerular filtration and by active tubular secretion following the same steps and mechanisms as the products of intermediate metabolism. Therefore, drugs that are filtered by the glomerulus are also subject to the process of passive tubular reabsorption. Glomerular filtration will only remove those drugs or metabolites that are not bound to proteins present in blood plasma (free fraction) and many other types of drugs (such as the organic acids) are actively secreted. In the proximal and distal convoluted tubules, non-ionised acids and weak bases are reabsorbed both actively and passively. Weak acids are excreted when the tubular fluid becomes too alkaline and this reduces passive reabsorption. The opposite occurs with weak bases. Poisoning treatments use this effect to increase elimination, by alkalizing the urine causing forced diuresis which promotes excretion of a weak acid, rather than it getting reabsorbed. As the acid is ionised, it cannot pass through the plasma membrane back into the blood stream and instead gets excreted with the urine. Acidifying the urine has the same effect for weakly basic drugs. On other occasions drugs combine with bile juices and enter the intestines. In the intestines the drug will join with the unabsorbed fraction of the administered dose and be eliminated with the faeces or it may undergo a new process of absorption to eventually be eliminated by the kidney.
=== Cardiovascular outcomes in type 2 diabetes === A major focus of McGuire's research has been understanding how antihyperglycemic therapies for type 2 diabetes affect cardiovascular risk. His work has helped establish the modern framework of cardiovascular outcome trials (CVOTs), emphasizing the need to demonstrate not only glycemic control but also cardiovascular safety and benefit. He has written on the evolving ethical and scientific challenges of trial design in an era when a number of antihyperglycemic medications have shown cardiovascular protection, advocating for creative trial designs for randomized assessment of novel agents against active comparators with established evidence of efficacy.
=== Normal–phase chromatography === Normal–phase chromatography was one of the first kinds of HPLC that chemists developed, but has decreased in use over the last decades. Also known as normal-phase HPLC (NP-HPLC), this method separates analytes based on their affinity for a polar stationary surface such as silica; hence it is based on analyte ability to engage in polar interactions (such as hydrogen-bonding or dipole-dipole type of interactions) with the sorbent surface. NP-HPLC uses a non-polar, non-aqueous mobile phase (e.g., chloroform), and works effectively for separating analytes readily soluble in non-polar solvents. The analyte associates with and is retained by the polar stationary phase. Adsorption strengths increase with increased analyte polarity. The interaction strength depends not only on the functional groups present in the structure of the analyte molecule, but also on steric factors. The effect of steric hindrance on interaction strength allows this method to resolve (separate) structural isomers. The use of more polar solvents in the mobile phase will decrease the retention time of analytes, whereas more hydrophobic solvents tend to induce slower elution (increased retention times). Very polar solvents such as traces of water in the mobile phase tend to adsorb to the solid surface of the stationary phase forming a stationary bound (water) layer which is considered to play an active role in retention.
HGPS is caused by mutations that weaken the structure of the cell nucleus, making normal cell division difficult. The histone mark H4K20me3 is involved and caused by de novo mutations that occur in a gene that encodes lamin A. Lamin A is made but is not processed properly. This poor processing creates an abnormal nuclear morphology and disorganized heterochromatin. Patients also do not have appropriate DNA repair, and they also have increased genomic instability. In normal conditions, the LMNA gene codes for a structural protein called prelamin A, which undergoes a series of processing steps before attaining its final form, called lamin A. Prelamin A contains a "CAAX" where C is a cysteine, A an aliphatic amino acid, and X any amino acid. This motif at the carboxyl-termini of proteins triggers three sequential enzymatic modifications. First, protein farnesyltransferase catalyzes the addition of a farnesyl moiety to the cysteine. Second, an endoprotease that recognizes the farnesylated protein catalyzes the peptide bond's cleavage between the cysteine and -aaX. In the third step, isoprenylcysteine carboxyl methyltransferase catalyzes methylation of the carboxyl-terminal farnesyl cysteine. The farnesylated and methylated protein is transported through a nuclear pore to the interior of the nucleus. Once in the nucleus, the protein is cleaved by a protease called zinc metallopeptidase STE24 (ZMPSTE24), which removes the last 15 amino acids, which includes the farnesylated cysteine. After cleavage by the protease, prelamin A is referred to as lamin A.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.